This article was originally published in The Rose Sheet
Executive SummaryAcquisition of tissue engineering company SkinEthic by French beauty marketer's Episkin subsidiary, which is dedicated to development of reconstructed skin, is aimed at helping L'Oréal enhance development of in vitro test methods, firm says in Feb. 28 release. SkinEthic is an "important worldwide player in the production and commercialization of human epidermal and epithelial tissues," including epidermis, dermis and corneal tissues, L'Oréal notes. "The acquisition of SkinEthic allows us to respond to the needs of the entire industry and more specifically in the area of alternative approaches to animal testing," firm adds. Marketing of most cosmetic products tested on animals is prohibited under 7th Amendment to EU's Cosmetics Directive beginning in 2009...
You may also be interested in...
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.